Find an expert

Professor Andreas Obermair is a gynaecological oncologist in public and private practice in Brisbane, Australia. He graduated from the University of Vienna, Austria (1990) and then went on to complete his specialist training in obstetrics and gynaecology (1999). He enrolled in gynaecological oncology sub-speciality training in 2000 (Brisbane and Perth) and since 2003 has been a part time staff specialist in gynaecological oncology at the Royal Brisbane and Women’s Hospital.

Professor Obermair is a NHMRC Investigator Fellow with the University of Queensland and is also the Director of Research in the Queensland Centre for Gynaecological Cancer where he drives a program of investigator-initiated surgical clinical trials. His mission is to make surgical treatments more humane, kinder and at the same time more effective.

His main research interests include clinical trials and hereditary (familial) gynaecological cancer. His main effort focusses on assembling a world-class team to conduct clinical trials that change the treatment of women affected by gynaecological cancer for the better. He authored more than 220 original articles in peer reviewed journals, teaches at the national and international level and maintains his international contacts at conferences. Professor Obermair conducts his private practice from Spring Hill in Brisbane, and on the Sunshine Coast.

I studied Technical Mathematics at the Vienna University of Technology. I also earned a Master's degree in Law and I finished the first ("non-clinical") part of Medical Studies at the University of Vienna. I earned my PhD in Applied Mathematics at the University of Vienna in 2007. My PhD advisor was Christian Schmeiser, my co-advisor was Peter Markowich. I spent several months at the University of Buenos Aires working with C. Lederman and at the ENS-Paris rue d'Ulm in the group of B. Perthame.

Before coming to UQ, I held post-doc positions at the Wolfgang Pauli Insitute (Vienna), University of Vienna and the Austrian Academy of Sciences (RICAM). In 2013 I won an Erwin Schrödinger Fellowship of the Austrian Science Fund (FWF). I was a post-doc researcher in the group of Alex Mogilner first at UC Davis, then at the Courant Institute of Math. Sciences (New York University).

I moved to UQ in Dec. 2016. More recently, in 2024, I spent 4 months at the department of Mathemetics of the U. of Heidelberg as a visiting scientist.

Dr. Melanie Oey is currently Research Officer at the Institute for Molecular Bioscience in the Group of Prof. Ben Hankamer. She was born in Berlin, Germany, and went to the University of Potsdam to study Biochemistry. During her studies she worked at the Max-Planck Institute of Molecular Plant Physiology in Golm, Germany, where she also received her Ph.D. in 2009 for her work on the production of lysin antibiotics in tobacco plants. In the same year she came to Australia to work at the University of Queensland, and has since then developed new technologies which are base for the newly launched "Breakthrough Science Program in Algal Biomedicine" at the Institute for Molecular Bioscience.

Her research interestes are:

- High value product production (e.g. vaccines, antibiotics, pain killer) in Algae via chloroplast and nuclear transformation

- Improvement of bio-hydrogen production from microalgae

- Development of new molecular tools for microalgae

Her work has been funded by the Australian Research Council (ARC), the National Health and Medical Research Council (NHMRC) and the German Academic Exchange Service (DAAD).

Dr. Ong is an exceptional and driven researcher in the field of Animal Health, and her work revolves around studying pathogen genomes, transcriptomes, and host-associated metagenomes to enhance animals' resistance to diseases and improve their overall health and productivity.

One remarkable aspect of Dr. Ong's expertise is her versatility and enthusiasm for both wet lab and dry lab (bioinformatics) work. She finds equal joy in conducting hands-on experiments in the wet lab and diving into data analysis and computational work in the bioinformatics domain. This multidisciplinary approach empowers her to gain comprehensive insights into her research subjects and tackle complex challenges from various angles. Dr. Ong's vast skillset encompasses molecular biology and expertise in utilizing 2nd and 3rd generation sequencing technologies, along with her proficiency in bioinformatics tools and techniques. This diverse knowledge allows her to explore and employ cutting-edge methodologies, providing her with a unique advantage in her research endeavors.

One of Dr. Ong's significant achievements was conducting the first cattle reproductive tract metagenomic study in Australia. This groundbreaking study likely contributed valuable information about the reproductive health of cattle and opened new avenues for further research in this area. Additionally, her contributions extend to the assembly of complete genomes for multiple pathogens, such as Campylobacter fetus and Bovicola ovis. This accomplishment is instrumental in understanding these pathogens' genetic makeup, evolution, and mechanisms of infection, which is vital in developing targeted strategies to combat diseases affecting animals.

Keywords: Microbiome and Metagenomics, Pathogen genomics, Animal health, PCR, Sequencing, Host-microbe interactions

In The Ortiz-Barrientos Lab we seek to understand how natural selection drives the origin of traits and new species. We combine empirical and theoretical approaches from across multiple disciplines.

We are located in beautiful Brisbane, Australia, in the School of The Environment at The University of Queensland.

Please explore our pages to learn about research, culture, and the team of scientists that bring their passion and creativity to discovering how nature works.

Professor Nathan Palpant is a cardiovascular scientist whose research integrates human genetics, computational genomics, stem-cell biology and drug discovery to understand the mechanisms of cardiovascular disease and translate these discoveries into new diagnostics and therapies.

His research focuses on why individuals differ in their susceptibility to heart disease, severity of myocardial injury and response to treatment. His laboratory studies inherited and environmental determinants of cardiovascular disease using population-scale genomics, human pluripotent stem-cell models and experimental models of cardiac injury. Major areas of research include myocardial infarction and cardioprotection, heart failure, inherited cardiovascular disease, cardiometabolic disease, complex-disease subtyping and precision medicine.

His research aims to connect fundamental discovery with clinical and commercial translation. His laboratory identified ASIC1a as a therapeutic target for myocardial injury, leading to first-in-class cardioprotective therapeutics now undergoing clinical development through Infensa Bioscience. He has also established Rosella Therapeutics to develop a new class of macrocyclic peptide therapeutics targeting cardiac muscle function to treat heart failure.

His broader research program develops genomic approaches for resolving biological subtypes of complex disease, functional genomics approaches for interpreting rare cardiovascular disease variants, and human stem-cell platforms for understanding genetic and environmental determinants of disease and drug response.

Marie-Odile Parat (MO) joined the School of Pharmacy as Senior Lecturer in December 2007.

MO obtained her Pharm.D. from University Joseph Fourier in Grenoble, France, a Masters in Cutaneous Biology from University Claude Bernard in Lyon, France and her Ph.D. in Cell Biology from University Joseph Fourier in Grenoble, France. She further has post graduate diplomas in the fields of Biomedical and Industrial Pharmacy, Photobiology, Pharmaceutical Management, and Public Health.

MO did her Pharmaceutical Residency at the University Hospitals of Grenoble, France in the Sterile Pharmaceutical Supplies Headquarters, the Department of Nuclear Medicine, and the Laboratory Medicine Department of Biochemistry. Attracted by international working experience, she carried out research within the R&D laboratories of Estee Lauder in Melville, NY. She further worked for the United Nations International Trade center in Geneva, Switzerland, where she was the Product Specialist on market information for pharmaceutical raw materials/essential drugs for three years in collaboration with the World Health Organization.

She later performed post-doctoral research in the Universidade de São Paulo, SP, Brasil and The Cleveland Clinic Foundation in the United States. She was appointed as a Staff Scientist in the Center for Anesthesiology Research of the Cleveland Clinic in 2003, an Assistant Professor of Molecular Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and a Member of the Case Cancer Center.

During her research career MO has attracted awards from various funding agencies including the Research Funding Agency of the State of São Paulo (FAPESP), the American Heart Association, the Ohio Cancer Research Associates, the American Cancer Society, the National Heart Foundation of Australia, Cancer Council Queensland, Australian and New Zealand College of Anaesthetists and the Australia Research Council (ARC).

The long term goal of the Parat laboratory is to provide insight for novel cancer therapies. A basic science team focusses on endothelial and cancer cell migration, invasion, angiogenesis, and specialized plasma membrane subdomains termed caveolae. A translational axis of research evaluates novel mechanisms by which opioids administered to cancer patients modulate the risk of long term tumour recurrence and metastasis. More recently, MO's work on mechanisms linking opioids to cancer is contributing to the OPICO consortium

I am a molecular virologist and ARC DECRA Fellow at the School of Chemistry and Molecular Biosciences, where I am Deputy Team Leader of the Infection and Immunity theme. My research focuses on RNA virus evolution, host immunity, and RNA technologies for vaccines and therapeutics, linking four connected themes:

• Virus discovery and evolution: identifying and characterising novel viruses across diverse hosts using metatranscriptomics, phylogenetics, and comparative genomics, with particular focus on orthoflaviviruses and orthomyxoviruses
• Host–virus interactions: understanding how innate immune and RNAi pathways shape infection outcomes in mammalian and arthropod systems
• Reverse genetics: developing CPER-based systems, reporter viruses, and replicons for mechanistic virology and rapid hypothesis testing
• RNA platforms: engineering self-amplifying RNA to tune stability, expression, and immune sensing for vaccines and therapeutics

I completed my PhD (2016–2021) at UQ's School of Biological Sciences under Prof. Sassan Asgari, where I characterised the virome of Aedes mosquitoes and their interactions with the endosymbiont Wolbachia. In 2021, I joined Prof. Alexander Khromykh's RNA Virology Laboratory at SCMB. There, I contributed to the development of the SARS-CoV-2 CPER reverse-genetics system and have worked routinely with PC3 pathogens, including West Nile virus, Japanese encephalitis virus, and SARS-CoV-2. In 2026, I commenced an ARC DECRA Fellowship to investigate how modified nucleotides shape RNA structure, immune sensing, and function in next-generation RNA technologies. My current work is funded by the ARC and NHMRC.

I provide bioinformatics and phylogenetics support within UQ and internationally, and welcome collaborations involving small RNA analysis, virus discovery and metatranscriptomics.

I served on the organising committee of MicroSeq (2023–2025), an Australasian conference promoting microbial sequencing research by early-career researchers. I am the Communications Officer for ASM Queensland (2024–) and an incoming Committee of Management member for the Australasian Virology Society (2026–).

Our research focuses on understanding how cells work and what goes wrong in disease. We are studying the role of cellular organelles in defence against pathogens, the molecular changes underlying muscle disease, and optimising methods to deliver therapeutics to specific cell types in whole animals.

Professor Robert Parton is an ARC Laureate Fellow, a group leader in the IMB Centre for Cell Biology of Chronic Disease, and Deputy Director of the Centre for Microscopy and Microanalysis. He is a Fellow of the Australian Academy of Science and an Associate Member of EMBO.

Ralph Patrick is a researcher focussed on understanding the molecular drivers of ageing and age-associated diseases and developing new therapeutic approaches to help alleviate diseases of ageing. He is trained as a computational biologist, with a BSc (Hons) and PhD from the University of Queensland (UQ). After completion of his PhD in 2016, he worked as a postdoctoral scientist at the Victor Chang Cardiac Research Institute (VCCRI) in Sydney for nearly six years. At the VCCRI, a major focus of his research was mapping out how the individual cells of the heart respond to a heart attack at the gene expression level and how these compare to other forms of chronic heart disease. Following the VCCRI, he joined the Ageing and Cellular Reprogramming lab at the IMB in 2022 as a postdoctoral fellow. His work at the IMB focusses on understanding the epigenetic and transcription factor drivers of the ageing process and leveraging this knowledge to develop new strategies for restoring youthful cell states. Any potential collaborators or students interested in this research area are welcome to contact him.

Dr Cassandra Pattinson research centres around exploring the effects of sleep and circadian rhythms on health, wellbeing, and recovery across the lifespan. Dr Pattinson is a Senior Research Fellow at the Child Health Research Centre (CHRC), an ARC Discovery Early Career Award (DECRA) Fellow, and a Senior Research Fellow as part of the the ARC centre of Excellence for the Digital Child. Her work has been supported by the ARC, NHMRC, NIH and the DSTG, as well as the Australian Federal Government and Queensland Government.

Her research has involved a range of populations from children and adolescents, through to military personnel and athletes. Dr Pattinson's research spans a range of study designs and methodologies, including longitudinal studies tracking large child cohorts (>2000 children), standard observation techniques, survey and individualised standard child assessment, as well as studies employing physiological (actigraphy, spectrometry) and biological (hormones, proteomic, genomic) designs. Dr Pattinson also has a strong track record in research translation, these have included manuscripts in top scientific journals, reports for government and non-government organisations, development of professional development programs, as well as designing and presenting vodcasts and resources (e.g. fact sheets, workshops) to parent groups, young adults, government departments and the early childhood sector.

At CHRC Dr Pattinson is a part of the Community Sleep Health Group. This group collaborates with many other groups around broader issues of sleep and technology, sleep and the environment (including disasters), mental health and wellbeing, pain, disability, and new technologies and approaches.

My research interests have concentrated on the molecular genetic analysis of multigene phenotypes of bacteria encompassing pathogenicity, bacterial degradation of synthetic environmental pollutants, photosynthesis and the synthesis of antitumour antibiotics. My PhD research focussed on plasmids and mapping of the genome of the human pathogen P. aeruginosa (Pemberton,and Holloway, 1972a; Pemberton,and Holloway,1972b;Pemberton and Holloway,1973). I continued this research as a postdoc at UC Berkeley with John Clark in the Department of Molecular Biology in the Wendell Stanley Virus laboratory. I am grateful to Mark Guyer who taught me how to isolate large plasmid DNAs. In Robley Williams lab I learnt how to use the Kleinschmidt and Zahn technique for spreading the plasmid DNA on an electronmicroscope grid and metal shadow the sample to visualise it under an electron microscope; I am grateful to Robley Williams for showing me how to metal shadow my samples (Pemberton,1973; Pemberton and AJ Clark,1973; Miller, Pemberton and Richards,1974;Pemberton,1974;Miller,Pemberton and Clark,1977). After advice from John Clark and when I returned to Australia and took up an appointment with UQ I decided to diversify my research. During my postdoc I worked alongside Anne Emerick who was working with the CAM (camphor degradation) plasmid. John Clark put me on her advisory panel (alongside Mike Doudoroff and Norberto Palleroni) making her my first PhD student. The bacterial degradation of such complex naturally occurring molecules such as camphor required a large number of steps requiring a large number of genes hence a large plasmid. I decided to determine if soil bacteria had evolved plasmids which encoded the degradation of man-made molecules. I chose the synthetic herbicide 2,4-D. My research was the first to identify, isolate and clone genes responsible for the degradation of a man-made molecule –moreover the 2,4-D degradation was encoded by a broad host range plasmid, providing an explanation of how microorganisms rapidly evolve the ability to degrade and recycle a vast array of worldwide synthetic environmental pollutants which cause a range of diseases from cancer to birth defects (Pemberton & Fisher, Nature, 1977). One of the most widely studied microorganisms is the bacterium Ralstonia eutropha JMP134 pJP4 (Hgr) which has an extraordinary ability to degrade and recycle the most complex and most toxic synthetic molecules (Don and Pemberton, J.Bacteriol, 1981;Schmidt et.al.,2011. Catabolic Plasmids.Encyclopedia of Life Sciences). Famously more recent studies have shown that there are genes and gene clusters encoding the degradation of plastics, explosives and chemical weapons of war . Detailed studies of bacterial genes involved in the environmental degradation and recycling of a wide range naturally occurring and synthetic molecules show that degradation genes and degradation gene clusters play a major role in the worldwide carbon cycle.

Photosynthesis is considered the most important biological process on earth. And one of the most intensively studied photosynthetic organisms is the bacterium Rhodobacter sphaeroides. To start the research a local strain of R.sphaeroides, designated RS601, was isolated by Bill Tucker (my first australian PhD student) from a water sample obtained from a roadside ditch in Brisbane (Pemberton and Tucker,1977;Tucker and Pemberton,1978;1979;1980). One of the first discoveries made with this strain was lysogenic conversion to antibiotic resistance by a naturally occurring virus .(JM Pemberton, WT Tucker - Nature, 1977).

Subsequently when this strain was infected withe the broad host plasmid RP1 carrying the mecuric ion transposon Tn501 chromosome transfer occurred. This allowed the construction of the first genetic map of a photosynthetic bacterium(Pemberton and Bowen, J.Bacteriol, 1981). Mapping revealed that the photosynthesis gene cluster was on the main chromosome. Remarkably chromosome transfer occurred from a site right next to the photosynthesis gene cluster with early transfer of the entire cluster into the recipent cell. This provides a potential mechanism for the evolution and spread of photosynthesis genes. A clone bank of RS601 was constructed using pHC79:: Tn5deltaBamH1. This vector allowed cosmid cloning into the BamH1 site of Tn5. These Tn5 cosmid clones were transposed onto the broad host range plasmid pR751. The ability to transfer the entire cosmid clone bank to a wide range of bacteria led to the first cloning and heterologous expression of a carotenoid gene cluster (Pemberton&Harding,Current Microbiology,1986 & 1987).This indicated that genes involved in photosynthesis could be transferred to and expressed in a range of unrelated non-photosynthetic bacteria. Subsequent heterologous expression of carotenoid genes in an increasing variety of plants led to the production of foods enriched in the precursors of vitamin A e.g. Golden Rice (Erik Stokstad, Science Nov 20, 2019) . Vitamin A deficiency is the major preventable cause of blindness in children under 5 years of age; it affects up to 500,000 children each year. Using the same clone bank in mapping experiments in Rhodobacter sphaeroides I observed a few pale colonies in which carotenoid biosynthesis was suppressed. Subsequent detailed analysis of one of these cosmids led to the discovery of the long sought master regulator (PpsR) of bacterial photosynthesis and provided the first detailed insight into the mechanism by which bacterial photosynthesis is regulated at the molecular level (A Gene from the Photosynthetic Gene Cluster of Rhodobacter sphaeroides Induces trans Suppression of Bacteriochlorophyll and Carotenoid Levels in R.sphaeroides and R.capsulatus (R.J.Penfold and JM Pemberton, Current Microbiology, 1991; Sequencing, Chromosomal Inactivation and Functional Expression in E.coli of ppsR a Gene which represses carotenoid and bacteriochlorophyll synthesis in Rhodobacter sphaeroides. RJ Penfold and JM Pemberton. J.Bacteriol May 1994).Early studies by Cohen-Bazire, Sistrom and Stanier (1957) revealed that oxygen and blue light had varying effects on photosynthesis in Rhodobacter. The effect of oxygen was profound. The effect of blue light was more muted. The initial sequencing of ppsR (Penfold and Pemberton, 1994) revealed the presence of only two cys residues suggesting a possible mechanism for the profound effect of oxygen on PpsR repressor activity. Studies of conformational changes/repressor activity of PpsR in the presence and absence of oxygen have produced mixed results(Gomelsky et al.,2000;Masuda and Bauer.,2002). In contrast the muted effect of blue light on photosynthesis appears to be due to the blue light sensitive, anti-repressor AppA. (Gomelsky and Kaplan,1995). It is not known if any other environmental signals modulate PpsR activity.The rhodobacter research led to the construction of pJP5603 which allowed the precise insertion of a defined segment of DNA into a bacterial genome (Penfold and Pemberton,1992 ; Zordan,Beliveau,Trow,Craig and Cormack, 2015). The technique was used to either add functional genes or groups of genes to a precise location in the genome or to precisely target and inactivate individual genes. The site of insertion/mutagenesis is tagged with an antibiotic resistance gene. This process is known as “recombineering” ( Zhang et al., 1988). As with all forms of mutagenesis there are “off target” mutations. The consequences of such ”off target” mutations can range from minimal to extensive.

In a study of a range of genes encoding secreted enzymes involved in the degradation of naturally-occurring biological polymers e.g xylanases, cellulases,amylases, chitinases etc I attempted to obtain secretion genes from Chromobacterium violaceum. Again using the pHC79:: Tn5deltaBamH1 vector used in the study of the photosynthesis genes (Pemberton&Harding,Current Microbiology,1986 & 1987) I constructed a cosmid clone bank of C.violaceum. The clone bank I constructed did not produce secretion genes but instead 2-3 of the clones expressed the intense purple pigmented violacein in E.coli(Pemberton,1986). Subsequent subcloning revealed the gene cluster occupied 8kb and transposon mutagenesis revealed intense blue and intense green intermediates. (Pemberton et.al.,Current Microbiology,1991). I am grateful to Trudy Grossman for the detailed study of this cluster which included sequence analysis and functional characterisation of the violacein biosynthetic pathway (August et al., 2000). The functional analysis of the violacein gene cluster revealed that VioA VioC and VioD belong to the PheA(phenol) /TfdB (2,4-D) group of FAD dependant mono-oxygenases. TfdB is encoded by the 2,4-D degradation gene cluster of the broad host range IncP plasmid pJP4 carried by Ralstonia eutropha JMP134. This provides a link between the degradation of a man-made molecule-2,4-D and the synthesis of an anti-tumour antibiotic-violacein. Remarkably, under certain circumstances this 2,4-D degradation pathway can convert 2,4-D into the well known plant antibiotic-protoanemonin (Blasco,R et al., 1995).In 1983 Burt Ensley , Barry Ratzkin and co-workers (Ensley et al.,Science,1983) discovered that the naphthalene dioxygenase gene from Pseudomonas putida enabled E.coli K12 to synthesise the famous blue dye indigo from tryptophan; a second gene, VioD, from the violacein gene cluster also enabled E.coli K12 to produce indigo (Cheah et al.,Acta Crystallographica,1998). Further studies using the violacein gene cluster led to the development of techniques and vectors that should allow cloning and stable, high level expression of more antibiotic biosynthesis pathways in E.coli K12, particularly pathways from the prolific antibiotic producers the Streptomycetes providing novel antibiotics in the fight against antibiotic resistant pathogens (Sarovich and Pemberton,2007; Philip,Sarovich and Pemberton,2008 & 2009;Ahmetagic & Pemberton, 2010 & 2011;Ahmetagic, Philip ,Sarovich,Kluver and Pemberton,2011).An article published in June 2013 by Stevens and co-workers PLoS ONE 8(5) showed that a native gene cluster from Streptomyces rimosus encoding tetracycline can be directly expressed in E.coli K12.

For the first time researchers have showed the expression of the violacein gene cluster in a eukaryote-the yeast Saccharomyces cerevisiae (Lee et al., 2013). Such a discovery may indicate that the violacein gene cluster can be expressed in organisms which range from microbes to man. It may also indicate that major pathways from microorganisms can be engineered and expressed in a range of eukaryotes. Since violacein is a potent anticancer agent it is of interest to determine if the violacein cluster engineered into bacteria of the microbiome of an animal reduces cancer rates. Alternatively it may be possible to engineer the violacein pathway directly into an animal and observe if cancer rates are reduced. In view of the purported prokaryotic ancestry of eukaryoyic organelles such as mitochondria and chloroplasts ,one possible way of boosting violacein synthesis in eukaryotic cells could be to integrate the violacein gene cluster into organelle DNA.

Finally, violacein is chemically related to the well known anti-cancer drug staurosporine and possesses anticancer, antifungal, anti-parasite, antibacterial and antiviral activities;it might be possible to synthesise structural variants of violacein with more potent activity against various cancers and drug/antibiotic resistant pathogens. Interestingly is now known that violacein producing bacteria associated with the skin microbiome of certain frogs provides some protection against extinction by the worldwide spread of ‘chytrid’ fungus(Harris et.al., 2009). In addition, frogs have been used in cancer studies and may provide a simple model to test the anticancer properties of violacein. Since the violacein gene cluster is expressed in a wide range of bacteria ( Dr D S Philip, personal communication;D.S/Philip.PhD Thesis 2010) and has potent activity against the malarial parasite Plasmodium falciparum and other mosquito borne parasites, there is the possibility that mosquitoes engineered to carry the violacein gene cluster might be resistant to parasite infection. The cluster could be stably incorporated in the genomes of bacteria normally inhabiting the surface or the gut of the mosquito.A recent patent application (United States Patent Application 20170280730) indicates that Chromobacterium introduced into the microbiome of mosquitoes is useful for the prevention of transmission of malaria and dengue virus.In addition, chemical modification of violacein may produce drugs with even higher levels of activity against parasites including the malarial parasite ( Wilkinson et al., 2020). Violacein has activity against the pandemic virus Covid19 and there is some knowledge of its mode of action (Duran et al., 2021). Testing may reveal if it has activity against both Kappa and Delta Covid19 variants.Violacein can inhibit infection by HIV and COVID (Doganci et al., 2022)

• Fellow, American Society for Microbiology
• Fellow, Australian Society for Microbiology

Selected Publications:

• Ahmetagic, Adnan, Philip, Daniel S., Sarovich, Derek S., Kluver, Daniel W. and Pemberton, John M. (2011) Plasmid encoded antibiotics inhibit protozoan predation of Escherichia coli K12. Plasmid, 66 3: 152-158. doi:10.1016/j.plasmid.2011.07.006
• Ahmetagic, Adnan and Pemberton, John M. (2011) Antibiotic resistant mutants of Escherichia coli K12 show increases in heterologous gene expression. Plasmid, 65 1: 51-57. doi:10.1016/j.plasmid.2010.11.004
• Ahmetagic, Adnan and Pemberton, John M. (2010) Stable high level expression of the violacein indolocarbazole anti-tumour gene cluster and the Streptomyces lividans amyA gene in E. coli K12. Plasmid, 63 2: 79-85. doi:10.1016/j.plasmid.2009.11.004
• Philip, Daniel S., Sarovich, Derek S. and Pemberton, John M. (2009) Complete sequence and analysis of the stability functions of pPSX, a vector that allows stable cloning and expression of Streptomycete genes in Escherichia coli K12. Plasmid, 62 1: 39-43. doi:10.1016/j.plasmid.2009.03.002

Biography

Dr Huadong Peng is a Group Leader and Senior Research Fellow at the UQ's Biosustainability Hub, Australian Institute for Bioengineering and Nanotechnology (AIBN), UQ. He is a Future Academic Leader in the Australia’s Food and Beverage Accelerator (FaBA), and part of ARC Centre of Excellence in Synthetic Biology (CoESB). He earned his PhD from Monash University in Nov 2018, followed by postdoctoral training at Imperial College London and the Technical University of Denmark until Dec 2023. Prior to his PhD, he received his Master Degree from the University of Chinese Academy of Sciences in 2013 and a Bachelor Degree from China Three Gorges University in 2010. Additionally, he worked as a research associate at Novozymes (now Novonesis) from Nov 2013 to Jan 2015.

Since Jan 2024, Dr Peng has led the Yeast Engineering and Synthetic Biology (YESBio) research group (10-15 members), focusing on sustainable biomanufacturing. His research interests include 1) developing innovative synthetic biology tools, such as gene assembly methods, CRISPR-based genome editing tools, and biosensors; 2) modular metabolic engineering for advanced microbial cell factories, 3) synthetic microbial communities and 4) emerging Bio+ enabling technologies for applications in food ingredients, biochemicals, biofuels, and biomedicines.

Dr Peng secured $4.8M funding as Chief Investigator ($2.1M to his team), including the prestigious Marie Skłodowska-Curie Fellowship. He has published 40+ peer-reviewed papers in prestigious journals, including Nature Microbiology, Nature Chemical Biology, Nature Communications. He actively contributes to the scientific community through editorial roles, including Associate Editor for Frontiers in Bioengineering and Biotechnology and Youth Editor for The Innovation (IF 26), BioDesign Research and mLife. He is also an invited peer reviewer for 30+ international journals and grants such as Nature Synthesis, ACS Synthetic Biology, etc.

Dr Peng is looking for highly motivated Honours, Master and PhD students, and highly competitive full scholarship may be provided. The University of Queensland ranks in the top 50 as measured by the Performance Ranking of Scientific Papers for World Universities. The University also ranks 45 in the QS World University Rankings, 52 in the US News Best Global Universities Rankings, 60 in the Times Higher Education World University Rankings and 55 in the Academic Ranking of World Universities.

Industry

Dr Peng is keen to translate the technologies developed by his team into real-world commercial applications, including advanced microbial cell factories, synthetic microbial communities, and optimised bioprocesses. These innovations enable the delivery of sustainable bio-solutions for industrial sectors spanning agri-food, industrial biotechnology and human health. He has established close collaborations with industry partners such as Woodside Energy, Noumi Operations, and Cauldron Fermentation, and he is actively engaging with additional partners, including Levur and NeweraBio.

Dr Peng has experience consulting with multiple companies and is open to taking on casual consulting roles as opportunities arise.

Selected Funding & Awards

Dr Peng has secured $4.8M funding as Chief Investigator ($2.1M to his team), including

• 2025 Australia’s Food and Beverage Accelerator (FaBA)-Cauldron ferm, $2M, CIB
• 2025 Australia’s Food and Beverage Accelerator (FaBA)-Noumi Operations, $2M, co-CIA
• 2025 NCRIS Synthetic Biology Voucher Scheme, $40K, CIA
• 2024 UQ Biosustainability hub seed funding, $50K, CIA
• 2024 Australia’s Food and Beverage Accelerator seed funding, $160K, CIA
• 2023 Chinese Government Award for Outstanding Self-financed Students Abroad, $15K
• 2022 Marie Skłodowska-Curie Fellowship ($266K, 8% success rate)

Key Publications (#, co-first author; *, corresponding author)

1. Chen, H.#, Peng, H.#, Ellis, T., & Ledesma-Amaro, R. Programmable cell–cell adhesion in synthetic yeast communities for improved bioproduction. Nature Chemical Biology 2026. https://doi.org/10.1038/s41589-025-02081-1
2. Peng, H.; Darlington, A. P. S.; South, E. J.; Chen, H.-H.; Jiang, W.; Ledesma-Amaro, R*. A molecular toolkit of cross-feeding strains for engineering synthetic yeast communities. Nature Microbiology 2024. 9(3), 848-863.
3. Park Y.-K., Peng H, Hapeta P., Sellés Vidal L. and Ledesma-Amaro R*. Engineered cross-feeding creates inter- and intra-species synthetic yeast communities with enhanced bioproduction. Nature Communications 2024, 15(1): 8924.
4. Aulakh S#, Vidal L#, South E#, Peng H, Varma S, Herrera-Dominguez L, Ralser M*, Ledesma-Amaro R*. Spontaneously establishing syntrophic yeast communities improves biosynthetic yield through shared labour. Nature Chemical Biology 2023, 19(8), 951-961.
5. Jiang W, Hernández V-D, Peng H, Liu L, Haritos VS, Ledesma-Amaro R* Metabolic engineering strategies to enable microbial utilization of C1 feedstocks. Nature Chemical Biology 2021, 17(8), 845-855. `
6. P Gao, Sun H., Ledesma-Amaro R., Marcellin E. and Peng H.* Advancements and Challenges in the Bioproduction of Raspberry Ketone by Precision Fermentation. Future Foods 2025: 100606.
7. Wen, Q., Xu, X., He, Q., Wang, C., Chen, Z., Zhong, W., Peng, H.*, Yang, M.*, & Xing, J*. Dual-pathway engineering enables robust vanillin bioproduction in Pseudomonas putida. Chemical Engineering Journal 2025, 526.
8. Peng, H.*; Chen, R.; Shaw, W. M.; Hapeta, P.; Jiang, W.; Bell, D. J.; Ellis, T.; Ledesma-Amaro, R*. Modular Metabolic Engineering and Synthetic Coculture Strategies for the Production of Aromatic Compounds in Yeast. ACS Synthetic Biology 2023, 12 (6), 1739-1749.
9. Peng, H.; He, L.; Haritos, V. S*. Flow-cytometry-based physiological characterisation and transcriptome analyses reveal a mechanism for reduced cell viability in yeast engineered for increased lipid content. Biotechnology for Biofuels 2019, 12 (1), 98.
10. Peng, H.; Chen, H.; Qu, Y.; Li, H.; Xu, J*. Bioconversion of different sizes of microcrystalline cellulose pretreated by microwave irradiation with/without NaOH. Applied Energy 2014, 117 (0), 142-148

Updated on 2 Jan 2026

I began my career working in industry for a company which specialised in in vitro diagnostic assays, for both human and veterinary health (AGEN Biomedical). There, I worked as a scientist for almost a decade in numerous departments of the commercialisation pipeline, including manufacturing, product development and research. Following this, I completed a PhD (2010) with the Australian Biosecurity Co-operative Research Centre for Emerging Infectious Disease and have since worked as a virologist at The University of Queensland.

My current research focuses on mosquito-borne virus discovery and the development of innovative vaccine and diagnostic platforms. Together, these research interests have culminated in a greater understanding of the mosquito virome and the development of new approaches for the detection of novel viruses. These include high throughput sequence and antigen-independent assays and the development of suites of unique monoclonal antibodies (mAbs), which in conjunction with deep sequencing platforms, provide comprehensive virus discovery strategies. Using this repertoire, I have been involved in the discovery and extensive genetic and phenotypic characterisation of new mosquito-borne viruses, belonging to more than six viral taxon (including Flaviviridae, Mesoniviridae, Bunyavirales, Reoviridae, Negevirus, Nodaviridae).

Harnessing the unique mosquito-specific growth restriction of the insect-specific flaviviruses that we discovered, my research now focuses on the application of these viruses to the development of novel, safe vaccines and diagnostics for multiple pathogenic flaviviruses.

Professor Pettit leads the Bones and Immunology Research Group at Mater Research Institute-UQ and is Director of Biomedical Research for Mater Research. Professor Pettit has led multidisciplinary research discovering intersecting biological mechanisms across the fields of immunology, rheumatology, cancer biology, haematology and bone biology. Professor Pettit is currently a UQ Amplify recipient associated with an ARC Future Fellowship, 2017-2020 and CIA on an NHMRC Ideas Grant, 2022-25. Major contributions led by Professor Pettit include the paradigm shifting discovery of a novel population of resident macrophages, osteal macrophages (osteomacs), and their role in promoting bone formation and bone regeneration after injury. Her team have published over 17 manuscripts based on this original discovery (with over 1700 citations) including translation of this basic research discovery toward eluciating novel disease mechanism from cancer bone metastasis to osteoporosis. This also led to the novel discovery of bone marrow resident macrophage contributions to supporting blood stem cells niches and the key role that these cells play in protecting this vital niche from cancer therapies. Bone marrow and specifically haematopoietic stem cell damage is one of the most serious and life-threatening side effects of cancer therapies. Here discoveries are cited in over 117 patent documents and she is currently collaborating with a major pharmaceutical partner.

Professor Pettit's leadership and achievements have been recognised through multiple awards including the 2019 UQ Faculty of Medicine Leader of the Year (Academic), Women in Technology 2018 Life Sciences Outstanding Achievement Award and becoming a Fellow of the American Society of Bone and Mineral Research. Professor Pettit has been invited to give numerous presentations at national and international conferences including Seoul Symposium on Bone Health, Asia-Pacific League of Associations for Rheumatology Congress and a prestigious American Society of Bone and Mineral Research Meet-the-Professor session. Professor Pettit is and Associate Editor for the Journal of Bone and Mineral Research, is an past Council member for the Australian and New Zealand Bone and Mineral Society, and chairs or serves on numerous committees including the Association of Australian Medical Research Institutes Gender Equity, Diversity and Inclusion Committee. PhD candidates under Professor Pettit's supervision have all been supported by scholarships (including 2 x NHMRC), received numerous local and national awards (e.g. Dr Alexander, ASMR QLD Premier Postgraduate Award, 2011 and Dr Lena Batoon won the UQ Faculty of Medicine Graduate of the Year Award, 2021), all had high quality first author publications at completion and 2 received UQ Dean’s Commendations.

Dr Sang Phan work combines research in forest ecology and management with significant experience as a practitioner in project implementation and a community development worker. Dr. Phan’s expertise includes carbon sequestration in terrestrial and coastal ecosystems (such as mangrove forests), sustainable forestry practices, and the valuation of ecosystem services. He translates this expertise into practical outcomes by leading forest restoration programs, designing climate change mitigation projects such as REDD+ and agroforestry carbon initiatives, and improving environmental monitoring techniques. A key aspect of his approach involves working directly with local communities and stakeholders, coordinating development projects, and delivering targeted training to build local capacity for sustainable land management and livelihood enhancement.

I got my BSc degree from the University of Natural Sciences in Vietnam. I spent the next two years working on characterisation of multi-drug resistant Mycobacterium tuberculosis with Dr Maxine Caws at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. I went to the Wellcome Trust Sanger Institute and the University of Cambridge, UK to do my PhD in Prof. John Wain lab where I studied molecular mechanisms affecting the stability of IncHI1 multidrug resistant plasmids in Salmonella Typhi. I then moved to Australia to join the group of Prof. Mark Schembri at the School of Chemistry and Molecular Biosciences, University of Queensland. I am now working on identifying novel virulent factors in uropathogenic E. coli, especially in the newly emerged but globally spread ST131 clone, using high-throughput transposon mutagenesis and next-gen sequencing. I also maintain my interest in plasmid biology and have started projects to study multidrug resistant plasmids carrying blaCTX-M-15 or blaNDM-1 resistant genes.

Dr Giovanni Pietrogrande is based at the Australian Institute for Bioengineering and Nanotechnology (AIBN), where he is the Synthetic Neuroimmunology Theme Leader.

He leads the development of advanced human brain and spinal cord organoid models to study neuroinflammation, demyelination and neurodegeneration, with a particular focus on how microglia, oligodendrocytes and other neural cells interact to drive diseases such as multiple sclerosis and motor neuron disease, and on using this knowledge to identify and test new therapeutic strategies. His research program is supported by competitive funding from HNMRC, MS Australia, MND Research Australia and FightMND, underscoring the translational impact and clinical relevance of his work.

Together with his team, he works on a broad range of problems, from engineering next-generation immune-based cell therapies and endowing central nervous system organoids with a functional immune system, to modelling their interactions with immune cells to fully reproduce neurodegenerative and neuroinflammatory pathologies. The group also leverages synthetic biology to design new strategies to rebalance neuroinflammation, promote remyelination and repair neural circuits.